Susquehanna International Group, LLP Larimar Therapeutics, Inc. Transaction History
Susquehanna International Group, LLP
- $641 Billion
- Q4 2024
A detailed history of Susquehanna International Group, LLP transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 67,579 shares of LRMR stock, worth $215,577. This represents 0.0% of its overall portfolio holdings.
Number of Shares
67,579
Previous 20,857
224.01%
Holding current value
$215,577
Previous $136,000
89.71%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding LRMR
# of Institutions
125Shares Held
66.8MCall Options Held
500KPut Options Held
61.2K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$67.7 Million2.01% of portfolio
-
Janus Henderson Group PLC London, X06.44MShares$20.6 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$19.3 Million0.37% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.65MShares$14.8 Million7.6% of portfolio
-
Goldman Sachs Group Inc New York, NY4.15MShares$13.2 Million0.0% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $138M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...